Name: GENOWAY SA (ALGEN) Stock
Brand: GENOWAY SA
Rating: 5 (3 reviews)

Question 1

Can you describe the business of GENOWAY SA?

Accepted Answer

genOway SA engages in the development of genetically modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 143 full-time employees. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.

Question 2

Can you provide the latest stock price for GENOWAY SA?

Accepted Answer

The current stock price of ALGEN.PA is 2.61 EUR. The price increased by 0.38% in the last trading session.

Question 3

Does GENOWAY SA pay dividends?

Accepted Answer

ALGEN.PA does not pay a dividend.

Question 4

How is the ChartMill rating for GENOWAY SA?

Accepted Answer

ALGEN.PA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.

Question 5

Can you provide the number of employees for GENOWAY SA?

Accepted Answer

GENOWAY SA (ALGEN.PA) currently has 128 employees.

GENOWAY SA (ALGEN.PA) Stock Price, Forecast & Analysis

ALGEN.PA Latest News, Press Relases and Analysis